Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6 Hydroxydopamine
2. 6-hydroxydopamine
3. 6-ohda
4. Hydrobromide, Oxidopamine
5. Hydrochloride, Oxidopamine
6. Oxidopamine
7. Oxidopamine Hydrobromide
1. 28094-15-7
2. 6-hydroxydopamine Hydrochloride
3. 5-(2-aminoethyl)benzene-1,2,4-triol Hydrochloride
4. 6-hydroxydopamine Chloride
5. Oxidopamine (hydrochloride)
6. 2,4,5-trihydroxyphenethylamine Hydrochloride
7. 6-hydroxydopamine Hcl
8. 9wbv30hxtl
9. 1,2,4-benzenetriol, 5-(2-aminoethyl)-, Hydrochloride
10. 5-(2-aminoethyl)benzene-1,2,4-triol;hydrochloride
11. 6-hydroxydopamine Hydrochloride;6-ohda Hydrochloride
12. Nsc-233898
13. Ncgc00094747-01
14. Dsstox_cid_25838
15. Dsstox_rid_81164
16. Dsstox_gsid_45838
17. 2-(2,4,5-trihydroxyphenyl)ethan-1-aminium Chloride
18. Oxidopamine Hcl
19. Cas-28094-15-7
20. 2,5-dihydroxytyramine Hydrochloride
21. Einecs 248-837-2
22. Unii-9wbv30hxtl
23. Nsc 233898
24. 5-(2-aminoethyl)-1,2,4-benzenetriol Hydrochloride
25. 5-(2-aminoethyl)-4-hydroxypyrocatechol Hydrochloride
26. 6-hydroxy Dopamine Hydrochloride
27. 4-(2-aminoethyl)-1,2,3-benzenetriol Hydrochloride
28. 6-hydroxydopaminehydrochloride
29. Mfcd00012895
30. 1,2,3-benzenetriol, 4-(2-aminoethyl)-, Hydrochloride
31. 6-ohda Hydrochloride
32. 6-hd Hcl
33. Mls002207273
34. Schembl718426
35. Spectrum1500450
36. Chembl451197
37. Dtxsid0045838
38. Wln: Z2r Cq Dq Eq &gh
39. Hms1920d14
40. Pharmakon1600-01500450
41. Bcp18603
42. Hy-b1081
43. Tox21_111324
44. Ccg-40236
45. Nsc233898
46. Nsc757259
47. Akos015894730
48. Tox21_111324_1
49. Cs-4648
50. Nsc-757259
51. Ncgc00094747-02
52. Ncgc00167769-04
53. 3,5-trihydroxyphenethylamine Hydrochloride
54. As-60772
55. Smr001306794
56. Db-047336
57. Ft-0638757
58. D87854
59. 4-(2-aminoethyl)-1,3-benzenetriol Hydrochloride
60. A876787
61. 6-ohda Hydrochloride6-hydroxydopamine Hydrochloride
62. J-016968
63. 1,3-benzenetriol, 4-(2-aminoethyl)-, Hydrochloride
64. 1,4-benzenetriol, 5-(2-aminoethyl)-, Hydrochloride
65. 6-hydroxydopamine Hydrochloride; 6-ohda Hydrochloride
66. Q27273318
67. 1,2,4-benzenetriol,5-(2-aminoethyl)-,hydrochloride(1:1)
68. 6-hydroxydopamine Hydrochloride, >=97% (titration), Powder
69. 1,2,4-benzenetriol,5-(2-aminoethyl)-, Hydrochloride (1:1)
70. 1,2,4-benzenetriol, 5-(2-aminoethyl)-, Hydrochloride (1:1)
| Molecular Weight | 205.64 g/mol |
|---|---|
| Molecular Formula | C8H12ClNO3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 205.0505709 g/mol |
| Monoisotopic Mass | 205.0505709 g/mol |
| Topological Polar Surface Area | 86.7 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 142 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Adrenergic Agents
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)
ABOUT THIS PAGE
A Oxidopamine Hydrobromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxidopamine Hydrobromide, including repackagers and relabelers. The FDA regulates Oxidopamine Hydrobromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxidopamine Hydrobromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Oxidopamine Hydrobromide supplier is an individual or a company that provides Oxidopamine Hydrobromide active pharmaceutical ingredient (API) or Oxidopamine Hydrobromide finished formulations upon request. The Oxidopamine Hydrobromide suppliers may include Oxidopamine Hydrobromide API manufacturers, exporters, distributors and traders.
click here to find a list of Oxidopamine Hydrobromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Oxidopamine Hydrobromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Oxidopamine Hydrobromide active pharmaceutical ingredient (API) in detail. Different forms of Oxidopamine Hydrobromide DMFs exist exist since differing nations have different regulations, such as Oxidopamine Hydrobromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Oxidopamine Hydrobromide DMF submitted to regulatory agencies in the US is known as a USDMF. Oxidopamine Hydrobromide USDMF includes data on Oxidopamine Hydrobromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Oxidopamine Hydrobromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Oxidopamine Hydrobromide suppliers with USDMF on PharmaCompass.
Oxidopamine Hydrobromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oxidopamine Hydrobromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxidopamine Hydrobromide GMP manufacturer or Oxidopamine Hydrobromide GMP API supplier for your needs.
A Oxidopamine Hydrobromide CoA (Certificate of Analysis) is a formal document that attests to Oxidopamine Hydrobromide's compliance with Oxidopamine Hydrobromide specifications and serves as a tool for batch-level quality control.
Oxidopamine Hydrobromide CoA mostly includes findings from lab analyses of a specific batch. For each Oxidopamine Hydrobromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oxidopamine Hydrobromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxidopamine Hydrobromide EP), Oxidopamine Hydrobromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxidopamine Hydrobromide USP).
LOOKING FOR A SUPPLIER?
